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By comparing two subsequent human tumor stages we previously described 
calcyclin as a new potential melanoma associated neoplastic progression marker positively 
linked with metastasis. In this study the calcyclin expression levels in a representative 
panel of human melanoma cell lines were correlated with the occurrence of DNase I 
hypersensitive (DH) regions and potential enhancer elements in a 6 kb genomic fragment 
spanning the human calcyclin gene. Examination of the chromatin structure of the 
transcription unit revealed no qualitative differences in DH sites within the panel of tested 
human melanoma cells, but especially the sequences around the transcription start site and 
a 1.5 kb upstream region appeared more accessible to the nuclease in frequently (BLM, 
MV3) as compared to poorly (530, 1F6) metastasizing cells. The genomic fragments that 
harbor one or more DH sites were subjected to functional analysis by luciferase reporter 
gene assays. Thus, an enhancer element was detected between 361 and 167 bp upstream 
of the transcription start site. This enhancer displayed equal activating potential (2-3 fold) 
both in weakly and in frequently metastasizing cells and was apparently recognized by 
transcription factors present in both types of human melanoma cell lines. We. conclude 
that, in addition to a slight amplification of the encoding gene, the elevated calcyclin 
mRNA levels are only reflected in a selectively increased accessibility of the chromatin
structure to DNasel in metastasizing melanoma cells © 1995 Academic Preas, Inc.
Calcyclin is a small calcium-binding protein (10.5 kD) belonging to the SI00 
family containing two calcium-binding structures, the so called EF hands. It was 
identified as a differentially expressed mRNA in serum-stimulated and quiescent fibro­
blasts [1,2] and was originally isolated from Gr specific temperature sensitive mutants of 
baby Syrian hamster kidney cells [3].
Although the function of calcyclin is still unknown, several observations can be 
made: the calcyclin gene was induced by serum, platelet-derived growth factor, or 
epidermal growth factor [1,4,5]. The gene product was shown to bind both zinc and 
calcium [6] which indicated that it is involved in processes related to signal transduction.
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Secondly, aberrant expression of calcyclin was reported for human myeloid leukemias [1], 
and overexpression was found to occur in thick melanomas as compared to thin ones [7]
and in raj-transformed metastatic NIH/3T3 cells [8]. Finally, the calcyclin protein was
reported to associate with other proteins. Murphy et al. [9] isolated calcyclin as a
prolactin receptor associated molecule. Interactions in a calcium-dependent manner were
reported for several members of the annexin family, among which annexin II, VI, and XI
[10,11,12]. Associations with glyceraldehyde-3-phosphate dehydrogenase [12], and sialic
acid [13] were also described.
By applying the differential hybridization technique to two subsequent stages of 
melanocytic tumor progression to identify new progression markers for human cutaneous 
melanoma, several differentially expressed clones were isolated, one of which appeared to 
be coding for calcyclin [14]. The expression of calcyclin was at least ten times elevated in 
the highly metastatic human cell lines BLM and MV3 as compared to the poorly metas­
tatic cell lines 530 and 1F6 (see Figure 1A). Correspondingly, a slight amplification of 
the calcyclin gene in the highly metastatic cell lines was reported although this could not 
directly account for the differences at the RNA level [14], The present study was 
undertaken to gain more insight in the regulation of the human calcyclin gene. With this 
purpose, we examined the expression profile in a number of human tissues and analyzed 
flanking sequences of the calcyclin promoter for enhancer activity in a panel of human 
melanoma cell lines with different metastatic behavior.
MATERIALS AND METHODS
Melanoma cell lines. Human melanoma cell lines MV3, BLM, 530, and 1F6 
[15,16] were grown as monolayers on Dulbecco’s modified Eagle’s medium (Gibco 
Laboratories, Grand Island, New York) supplemented with 10% fetal calf serum (Gibco 
Laboratories), glutamine (2 mM), penicillin G (100 units/ml), streptomycin (100 /xg/ml), 
and pyruvate (1 mM). Within this panel of cell lines, 1F6 and 530 represent the poorly 
metastasizing cell lines, with a metastasis frequency of less than 10% three months after 
subcutaneous inoculation into nude mice. The cell lines BLM and MV3 represent the 
highly metastatic phenotype, with over 50% metastasis frequency.
Isolation and analysis of RNA. Total cellular RNA was isolated using the 
lithium-urea procedure as described by Auffray and Rougeon [17]. Ten micrograms of 
total RNA were glyoxylated [18], size fractionated on 1% agarose gels, and transferred to 
Hybond N-plus filters (Amersham, England). Hybridization was performed according to 
Church and Gilbert [19] with the addition of 0.1 mg denatured herring sperm DNA/ml of 
hybridization mixture. To confirm that equal amounts of RNA were loaded in each lane, 
the blots were hybridized afterwards to a 28S ribosomal probe.
Mapping of DNase I hypersensitive sites. Nuclear isolations, DNase 1 digestions 
and chromosomal DNA purifications were all performed as described by Dirks et al. 
[20]. Purified DNA (100 ¡xg samples) was digested to completion with £a?Rl (Gibco 
Laboratories), purified by phenol and chloroform extractions, precipitated, and dissolved
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in TE (10 mM Tris-HCl pH 8.0, 1 mM EDTA). DNA samples (50 \xg) were electropho- 
resed in vertical 1 % agarose gels (6 mm thick) and transferred to Hybond N-plus filters. 
The H indlll fragments of phage lambda (400 ng/lane) and the HaeIII fragments of phage 
<jf>X174 (200 ng/lane) were added to each sample as internal molecular size marker. DNA 
was hybridized overnight in 0.75 M NaCl, 75 mM sodium citrate, 0.1% SDS, 0.1% 
Ficoll, 0.1% BSA, 0.1% polyvinylpyrrolidine, 100 /¿g/ml denatured herring sperm DNA 
at 68°C with 32P-labeled DNA probes. Filters were washed at 68°C in 15 mM NaCl, 1.5 
mM sodium citrate, 0.1% SDS and exposed to Kodak X-Omat AR-5 films.
DNA probes. The human calcyclin gene, a 6 kb EcoBl fragment cloned in pUC9, 
was a generous gift from Dr. R. Baserga (Temple University Medical School, Philadelp­
hia). After subcloning the 5 ’ 0.5 kb EcoM -BamKI and 3 ’ 0.4 kb Bam lll-EcoRl fragments 
(see figure 4) from the human calcyclin gene, they were used as probes in mapping the 
DNase I hypersensitive regions. pMWl is a pUC18 derived vector containing the entire 
calcyclin coding region in a 362 bp cDNA fragment [14].
Reporter gene constructs. For progressive deletions of the 5 ’-flanking region, the 
3.0 kb Bam ffl fragment of human calcyclin gene containing the first exon, was digested 
with Smal, Xhol, Sphl, Ncol and Seal, The recovered Smal-Bamlll (-167/+  134) Xhol- 
B am lll (-361/+  134), Sphl-BamBX (-588/ +  134), N col-B am lll (-1194/+134), Scal-BamHl 
(-1370/+ 134) fragments and the 3.0 kb Bam Bl fragment containing the first exon, were 
filled in and ligated into the Bgfll site of the promoterless luciferase gene vector pGL,ba- 
sic (Promega, Madison, WI).
Electropermeations and luciferase assays. Supercoiled plasmid DNA was 
purified by CsCl gradient centrifugation [21] and quantitated by means of both EtBr 
staining and spectrophotometric measurements. Cells were washed three times with PBS. 
2 x 107 cells were mixed with 10 f i g  pCHllO (Pharmacia Sweden) and 10 pmol luciferase 
construct in 500 /xl PBS. After an incubation of 10 min on ice, cells were electropermea­
ted in a 1 ml electroporation cuvette (Eurogentec, Belgium) by a 2000 volt (530 and 1F6) 
or 1500 volt (MV3 and BLM) pulse from an ISCO type 494 power supply, so that cell 
survival was 60-70 %. Cells were incubated on ice for 10 min and replated on 10 cm 
petridishes (Nunc). 48 h after electroporation, cells were lysed in 150 fil of cell lysis 
buffer (25 mM Bycine pH 7,8, 0,05% Tween-20, 0,05% Tween-80) for 10-15 min at 
room temperature and cleared by centrifugation. The protein content of each lysate was 
determined in a protein assay (Biorad, Richmond, CA) and fixed amounts of protein were 
tested for ft-galactosidase activity [22]. For each cell line in individual experiments, 
amounts of protein corresponding to equal fl-galactosidase activity were used for lucifera­
se activity assays. 5-15 fig of cell extract, adjusted to 20 fxl total volume with cell culture 
lysis buffer were mixed with 100 [A assay reagent (20 mM Tricine, 1.07 mM (MgCO 
3)4M g(0H)2.5H20 , 2.67 mM M gS04, 0.1 mM EDTA, 33.3 mM dithio-threitol, 270 fiM 
coenzyme A, 470 /xM luciferin, 530 ¡jM ATP at room temperature) after which the 
activity was measured for 1 min in a Beckman model 2800 liquid scintillation counter. 
The luciferase activities were expressed as square root of measured counts per minute 
(cpm) minus background cpm.
RESULTS
human
calcyclin mRNA is expressed at highly variable levels in the human melanoma cell lines 
used in this study. Nuclear run-on assays confirmed that the transcription activity was 
higher in MV3 than in 1F6 (unpublished results). To obtain further clues about the 
regulation o f calcyclin expression, we determined its expression profile in normal human
1124
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Figure 1. Northern blot analysis calcyclin mRNA in a panel of human melanoma cell 
lines (A) and in normal human organs (B). Ten \x% of total RNA was loaded in each 
lane. pMWl was used as a molecular probe. The molecular weight marker was lambda 
DNA digested with restriction enzyme M/zdlll; a 28S ribosomal probe was used for the 
control hybridization.
Panel A: Lane 1: 530; lane 2: 1F6; lane 3: BLM; lane 4: MV3.
Panel B: Lane 1, kidney cortex; lane 2, kidney medulla; lane 3, lung; lane 4, muscle; 
lane 5, liver; lane 6 , placenta; lane 7, spleen; lane 8 , prostate; lane 9, intestines.
organs using northern blot analysis (Fig. IB), highest expression was found in spleen,
Weak
liver, muscle, kidney cortex and medulla.
elements for the human
(MV3
BLM) and the poorly metastatic (1F6, 530) cell lines for the presence of DNase I 
hypersensitive (DH) sites. Using two probes, one hybridizing at the upstream extremity of 
a 6.0 kb EcoRI genomic fragment (Fig. 2A) and the other at the downstream extremity 
(Fig. 2B), ten DH sites were detected around the three exons long calcyclin gene in the 
four human melanoma cell lines. The most prominent DH region included the calcyclin 
gene promoter and extended from -0.3 to +0.3 kb relative to the transcription start site.
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Figure 2. Mapping of the DNase I hypersensitive sites in the 6.0 kb EcoJU calcyclin gene 
fragment. Nuclei from the indicated cells were treated with increasing amounts of DNase 
I. Chromosomal DNA (50 /¿g/lane) was digested with EcoHl and subjected to Southern 
blot analysis. The probes used were the 5’ 0.5 kb EcoRI-BamHl (panel A) or the 3’ 0.4 
kb BaniHI-EcoKl (panel B) fragment. DNase I concentrations were: a, 0 u/ml; b, 64 
u/ml; c, 128 u/ml; d, 256 u/ml; e, 512 u/ml; f, 1024 u/ml; g, 2048 u/ml; h, 4096 u/ml. 
By using endogenous markers for DNA fragment length we established the positions of 
the DH sites relative to the transcription start site.
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BLM, while it was virtually absent in 1F6 and 530 (Fig. 2B). The other DH sites appear 
only at higher DNasel concentrations and may be less important for transcriptional control 
(see also below). The DH sites downstream of the transcription start (+ 1 .9 , + 2 .3 , + 2 .6  
kb) may also be the result of transcription termination.
To study the possibility that the marked differences in calcyclin mRNA expression 
are modulated by variations in the levels of transactivating factors in human melanoma 
cell lines, we performed a functional analysis of the calcyclin promoter element including 
the relevant flanking regions as defined by the presence of DH sites. Progressively 
deleted sequences of the 5 ’ -flanking region o f the calcyclin gene were fused to the coding 
sequence of the luciferase gene (Fig. 3A). The truncated promoter element constructs 
were transiently transfected by electroporation into the four melanoma cell lines. In each 
cell line the activity of the -167/+  134 bp Smal-BamHI calcyclin promoter fragment was 
arbitrarily defined as 100%. The profiles of relative luciferase reporter gene activities 
were essentially the same in the four tested melanoma cell lines. The experiments were
repeated three times with 1F6 and MV3 as two representative cell lines (Fig. 3B). We 
observed a 2-3 fold increase in luciferase reporter activity when the -167 /+  134 Smal- 
BamHI fragment was extended upstream to the -361/+134 XhoI-BamHI fragment. This 
effect was detected in both 1F6 and MV3. Further upstream extensions hardly induced 
additional changes in the luciferase reporter gene expression in the cell lines. This was 
also true for construct 5 which included the DH region at -1.5 kb (Fig. 3A). Constructs 
in which the orientation of the various fragments upstream of the -167/+  134 fragment 
were reversed (anti-sense) were inactive. We also tested the + 1366 /+ 2086  Rsal-BamHl 
fragment which harbors DH sites +2.5  and + 1 .85  by cloning it upstream (sense and anti­
sense) of the -167/+134 Smal-BamHI calcyclin/luciferase fusion gene. As can be seen in 
fig. 3B no significant effects were observed.
DISCUSSION
The calcyclin gene, which is cell cycle-regulated and can be induced by several 
growth factors, was identified as a differentially expressed gene when comparing two 
subsequent stages of melanocytic tumor progression. Calcyclin mRNA expression 
positively correlated with metastatic potential o f the human melanoma cell lines [14].
4
To obtain clues about its regulation, we examined the human tissue distribution of 
calcyclin at the mRNA level. High calcyclin expression was found in lung, spleen and 
intestines, and a moderate expression in prostate and placenta. In contrast, calcyclin 
mRNA expression was low in rat spleen [14,23]. Although we postulated before that a
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Figure 3. Schematic overview (A) and relative promoter/enhancer activity (B) of the 
calcyclin/luciferase gene fusion constructs.
Panel A: DH sites in the 6.0 kb EcoBl calcyclin gene fragment are indicated by arrows. 
The three exons are given as boxes. E, £c<?RI; B, BaniHl; Sc, Seal; R, Rsal', Sp, Sphl; 
X, Xhol\ Sm, Smal] N, JVcoI; R, Rsal. Calcyclin constructs placed upstream of the 
luciferase reporter gene were: 1, -167/4-134 Smal-BamHI; 2, -361/+ 134 Xhol-BamHl; 3, 
-588/+ 134 Sphl-BamHl; 4, -1194/ + 134 Ncol-BamHl; 5, -1370/ + 134 Seal-BamHl; 6 , - 
3.0 kb/ +134 BamHl-BamHl; 7, +1366/+2086 Rsal-BamHl in front of -167/ + 134 Smal- 
BamHI, 8 , +2086/+1366 BamHl-Rsal in front of -167/+ 134 Smal-BamHI.
Panel B: Transient transfections of the fusion constructs into the human melanoma cell 
lines MV3 and 1F6. Electropermeations, fl-galactosidase assays, and luciferase assays 
were performed as described in Materials and Methods. Results were normalized to mean 
6-galactosidase activity obtained from co-electroporated pCHllO. For background correc­
tions we used the promoterless pGLi-control. Activities of all constructs are indicated as 
values relative to the activity of the -167/134 Smal-BamHI calcyclin/luciferase gene fusion 
construct. All data are mean values from three independent electroporations. Standard 
deviations are indicated by error bars.
high calcyclin mRNA expression might be ascribed to expression in smooth muscle cells 
present in these organs, a high expression in organs such as the intestines, placenta and 
the lungs can well be explained by the presence of the lining epithelium which is involved
in the secretion of mucus or other substances. Data on protein expression of calcyclin
i
showed that in some human organs such as muscle and placenta, calcyclin protein was
1129
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present in fibroblasts, whereas- in the majority of other human organs calcyclin was also 
found in different kinds of epithelial cells [24]. However, calcyclin protein was also 
detected in other cell types, notably melanocytes [14,25]. Recently, calcyclin was
permeabilized
manner
connection with the annexins which promote the fusion of membranes is therefore 
intriguing [10,11,12,28]. The mRNA expression pattern in human organs is in line with a
role for calcyclin in secretion pathways.
Since the increased mRNA expression of calcyclin in the highly metastasizing 
melanoma cell lines could only partially be explained by gene amplification (at the most 
twofold between cell lines 1F6 and MV3), we sought additional explanations for the 
elevated mRNA levels. Examination of the chromatin structure of the human calcyclin 
transcription unit present on a 6.0  kb EcoRI fragment indeed revealed two regions (DH
sites 0 .0  and enhanced
the highly metastatic cells. By contrast, no phenotype specific DH sites could be identi­
fied within the panel of human melanoma cell lines tested. In addition, the transient 
expression assays with luciferase reporter gene vectors did not reveal differential 
promoter/enhancer activities in the analyzed calcyclin flanking sequences. The calcyclin 
promoter, contained in a Smal-BamHl fragment (-167 to +134) and included in DH site 
0.0 (extending from -0.3 to +0.3), was active in all four human melanoma cell lines, 
which means that necessary transcription factors were present in the cell lines. The 
calcyclin promoter element includes a TATAA box, three GC boxes, and an enhancer-like 
structure [3]. When the calcyclin promoter element was extended upstream with 194 bp (- 
361/+  134 Xhol-BamBl), the luciferase activity was upregulated 2-3 fold in all cell lines. 
A further extension upstream of the calcyclin promoter element had no significant effect 
on the luciferase activity.
The enhancer activity present in the Xho\-Sma\ region (-361/-167) coincides with 
the DH site 0.0. Differences in DH sites arise from nucleosome clearance of chromatin 
and changes in nucleosome spacing. Because of the intensity of DH site 0.0, it probably 
spans both promoter and enhancer. The lower accessibility o f DH site 0.0 in the poorly 
metastasizing cell lines 1F6 and 530 may reflect normal nucleosome arrangements and 
related gene expression levels, while the chromatin structure of this region may be more 
disturbed in MV3 and BLM due to the reported rearrangements [14] and, consequently, 
more accessible to the relevant transcription factors. cannot
enhancer
enhanced
, the present results support the view that the
♦ » « «4 I t  «melanoma cell lines can be
1130
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ascribed to genomic rearrangements causing both gene amplification and increase in 
accessibility of the enhancer/ promoter sequences.
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